The whole blood system can be used to assess candidate drug mode-of-action to evaluate immune recall responses.
We use the whole blood system to test the mode-of-action of Immuneed’s therapeutic prostate cancer vaccine. The vaccine incorporates long peptides harboring several T cell epitopes. These long peptides are efficiently delivered to specific immune cells by Immuneed’s TET (tetanus-epitope targeting) system (Read more: Immuno-Oncology TET platform).
As a test for recall responses, Immuneed also makes use of the NLV epitope incorporated into a synthetic long peptide CMV-NLV. By sampling blood from HLA-A201+/CMV+ donors, recall responses to the NLV epitope can be studied using flow cytometry and staining for CD8, tetramer+ cells along with intracellular IFNγ/TNFα production. It is also possible to assess candidate drug mode-of-action to evaluate whether the recall responses can be improved by addition of your candidate drug.